Low-dose Naltrexone Therapy for Psoriasis
Author(s): Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Issue: Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue
Page(s): 94-96
Download in electronic PDF format for $65
Abstract: Safe, inexpensive, and convenient psoriasis therapy is desirable. Two recent case reports suggested that low-dose naltrexone is effective. Cases from our practice are presented in order to further the evidence of efficacy and safety of low-dose naltrexone in the treatment of psoriasis. Patients included 13 females, 2 males; mean age 57 years; mean psoriasis duration 16 years. Of the patients, 8 had psoriatic arthritis. In the past, 5 had completely failed and 10 had partially responded to =1 topical therapies. Patients used a self-assessed Likert scale on the effect of low-dose naltrexone on their psoriasis: 1 - worse; 2 – unchanged; 3 - slightly improved; 4 - somewhat improved; 5 – marked improvement. The response to 4.5 mg of oral naltrexone was as follows: 8/15 marked improvement; 2/15 somewhat improved; and 5/15 unchanged. Three adverse events included insomnia, diarrhea, and self-limited headache. Marked improvement was seen by 53% of the 15 patients. Low-dose naltrexone regulates lymphocyte responses, reduces cytokine production, and likely reduces mast cell activity. Low-dose naltrexone is safe, inexpensive, and appears be effective in this open-label study.
Related Keywords:
Leonard B. Weinstock, MD, Jill Cottel, MD, Lindsey Aldridge, RN, Alexander Egeberg, MD, PhD, low-dose naltrexone, plaque psoriasis, psoriatic arthritis, skin disorders, dermatosis, pruritus, adverse effects, clinical study
Related Categories:
DERMATOLOGY, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION, PATIENT ASSESSMENT
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
|
Mar/Apr 2020
Pg. 94-96
|
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Ploesser Jennifer, Weinstock Leonard B, Thomas Erin
|
Mar/Apr 2010
Pg. 171-173
|
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
|
Jul/Aug 2018
Pg. 270-278
|
Basics of Compounding: Clinical Studies
Allen Loyd V Jr
|
Nov/Dec 2002
Pg. 443-447
|
Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M, Collin Michael
|
May/Jun 2016
Pg. 197-201
|
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
|
May/Jun 2010
Pg. 182-192
|
Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A, Fokken Dawn
|
Sep/Oct 2009
Pg. 386-389
|
Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers
McCluskey Susan V, Sztajnkrycer Matthew D, Jenkins Donald A, Zietlow Scott P, Berns Kathleen S, Park Myung S
|
Sep/Oct 2014
Pg. 432-437
|
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Cote Brianna, Ross Bethany, Fortner Jeff, Rao Deepa
|
May/Jun 2018
Pg. 252-256
|
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
|
May/Jun 2022
Pg. 248-254
|